KRAS and non-small cell lung carcinoma: To further explore the activity of KRAS G12C inhibitor plus pemigatinib combinations, we applied an EMT signature analysis to available gene expression data for a set of NSCLC PDX models in order to select models with more mesenchymal or epithelial phenotypes [27] (S1 Fig).